Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Standard BioTools ( (LAB) ) has provided an update.
On June 22, 2025, Standard BioTools Inc. announced a strategic sale of its subsidiaries, including SomaLogic, to Illumina, Inc. for up to $425 million. This transaction aims to simplify Standard BioTools’ operations, achieve adjusted EBITDA break-even, and retain strategic upside through royalties and commercialization rights. The deal reflects improvements made to the business and aligns with the company’s focus on profitability and long-term value creation.
The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
Standard BioTools faces significant financial challenges with persistent losses and declining revenue. Technical indicators suggest bearish momentum, and the stock’s valuation is unattractive due to a negative P/E ratio. However, strategic initiatives and financial discipline noted in the earnings call offer some positive prospects for future improvement.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. operates in the life sciences sector, focusing on aptamer-based and functional proteomics, with products like KREX, Single SOMAmer, and diagnostic assays. The company retains its mass cytometry and microfluidics businesses while pursuing a disciplined M&A strategy targeting high-potential assets in pharma, bioprocessing, and clinical research.
Average Trading Volume: 1,271,236
Technical Sentiment Signal: Sell
Current Market Cap: $398.8M
For a thorough assessment of LAB stock, go to TipRanks’ Stock Analysis page.